Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. - Morris, J. A.; Hanson, J. E.; Steffen, B. J.; Chu, A. H.; Chi-Burris, K. S.; Gotz, V. P.; Gordon, R. D. (Clinical Transplantation, 2005)